Janux Therapeutics, Inc.
About Janux Therapeutics, Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$113.6M
- Total assets
- $1.0B
- Market cap
- $814.8M
- Operating margin
- -1576.7%
- Net margin
- -1136.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $10.0M
- Operating expenses
- $167.7M
- Operating income
- -$157.7M
- Income tax
- $0
- Net income
- -$113.6M
- EPS (basic)
- $-1.83
- EPS (diluted)
- $-1.83
Balance sheet
- Total assets
- $1.0B
- Current assets
- $975.9M
- Total liabilities
- $44.7M
- Current liabilities
- $25.0M
- Shareholders’ equity
- $956.8M
Cash flow
- Operating cash flow
- -$82.2M
- Investing cash flow
- -$301.0M
- Financing cash flow
- $4.9M
- Net cash flow
- -$378.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $814.8M
- EPS (diluted)
- $-1.83
- Shares outstanding
- 60.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 11, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $113.6M.
- Revenue grew 175% from FY2021 to FY2025.
- Trading 61% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Janux Therapeutics, Inc..
Write a review
News about Janux Therapeutics, Inc.
News & sentiment via Polygon.io
